Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study

The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the effect of pneumococcal polysaccharide conjugated vaccines (PCV). The objective of this study was to estimate the direct costs of hospitalized IPD cases. A prospective study was made in children aged <5 years diagnosed...

Descripción completa

Detalles Bibliográficos
Autores: Hernández S; Navas E; Aznar, I.; Ciruela P; García, J.; Moraga-Llop F; Muñoz, C.; Codina G; Fernández de Sevilla, M.; González-Peris S; Esteva, C.; Planes AM; Izquierdo C; Martínez, J.; Campins M; Uriona S; Salleras L; Serrano, A.; Jané M; Domínguez A
Tipo de documento: Artículo
Estado:Published version
Fecha de publicación:2020
País:España
Institución:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p17958
Acceso en línea:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17958
Nivel de acceso:Acceso abierto
Palabra clave:PCV7
PCV13
invasive pneumococcal disease
direct cost
_version_ 1878736545718992896
author Hernández S
author2 Navas E
Aznar, I.
Ciruela P
García, J.
Moraga-Llop F
Muñoz, C.
Codina G
Fernández de Sevilla, M.
González-Peris S
Esteva, C.
Planes AM
Izquierdo C
Martínez, J.
Campins M
Uriona S
Salleras L
Serrano, A.
Jané M
Domínguez A
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author_browse Aznar, I.
Campins M
Ciruela P
Codina G
Domínguez A
Esteva, C.
Fernández de Sevilla, M.
García, J.
González-Peris S
Hernández S
Izquierdo C
Jané M
Martínez, J.
Moraga-Llop F
Muñoz, C.
Navas E
Planes AM
Salleras L
Serrano, A.
Uriona S
author_facet Hernández S
Navas E
Aznar, I.
Ciruela P
García, J.
Moraga-Llop F
Muñoz, C.
Codina G
Fernández de Sevilla, M.
González-Peris S
Esteva, C.
Planes AM
Izquierdo C
Martínez, J.
Campins M
Uriona S
Salleras L
Serrano, A.
Jané M
Domínguez A
author_role author
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
description The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the effect of pneumococcal polysaccharide conjugated vaccines (PCV). The objective of this study was to estimate the direct costs of hospitalized IPD cases. A prospective study was made in children aged <5 years diagnosed with IPD in two high-tech hospitals in Catalonia (Spain) between 2007-2009 (PCV7 period) and 2012-2015 (PCV13 period). Costs were calculated according to 2014 Catalan Health Service rates using diagnostic-related groups. In total, 319 and 154 cases were collected, respectively. Pneumonia had the highest cost (65.7% and 62.0%, respectively), followed by meningitis (25.8% and 26.1%, respectively). During 2007-2015, the costs associated with PCV7 serotypes (Pearson coefficient (Pc) = -0.79;p= 0.036) and additional PCV13 serotypes (Pc = -0.75;p= 0.05) decreased, but those of other serotypes did not (Pc = 0.23p= 0.62). The total mean cost of IPD increased in the PCV13 period by 31.4% (euro3016.1 vs. euro3963.9), mainly due to ICU stay (77.4%; euro1051.4 vs. euro1865.6). During the PCV13 period, direct IPD costs decreased due to a reduction in the number of cases, but cases were more severe and had a higher mean cost. During 2015, IPD costs increased due to an increase in the costs associated with non-PCV13 serotypes and serotype 3 and this requires further investigation.
eu_rights_str_mv openAccess
format article
id ES_90ec1fd5287c90b28f75e89eceff5baf
institution Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
network_acronym_str ES
network_name_str España
oai_identifier_str oai:fsjd.fundanetsuite.com:p17958
publishDate 2020
publishDateSort 2020
publisher MDPI
publisherStr MDPI
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
spelling Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study Hernández S Navas E Aznar, I. Ciruela P García, J. Moraga-Llop F Muñoz, C. Codina G Fernández de Sevilla, M. González-Peris S Esteva, C. Planes AM Izquierdo C Martínez, J. Campins M Uriona S Salleras L Serrano, A. Jané M Domínguez A PCV7 PCV13 invasive pneumococcal disease direct cost The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the effect of pneumococcal polysaccharide conjugated vaccines (PCV). The objective of this study was to estimate the direct costs of hospitalized IPD cases. A prospective study was made in children aged <5 years diagnosed with IPD in two high-tech hospitals in Catalonia (Spain) between 2007-2009 (PCV7 period) and 2012-2015 (PCV13 period). Costs were calculated according to 2014 Catalan Health Service rates using diagnostic-related groups. In total, 319 and 154 cases were collected, respectively. Pneumonia had the highest cost (65.7% and 62.0%, respectively), followed by meningitis (25.8% and 26.1%, respectively). During 2007-2015, the costs associated with PCV7 serotypes (Pearson coefficient (Pc) = -0.79;p= 0.036) and additional PCV13 serotypes (Pc = -0.75;p= 0.05) decreased, but those of other serotypes did not (Pc = 0.23p= 0.62). The total mean cost of IPD increased in the PCV13 period by 31.4% (euro3016.1 vs. euro3963.9), mainly due to ICU stay (77.4%; euro1051.4 vs. euro1865.6). During the PCV13 period, direct IPD costs decreased due to a reduction in the number of cases, but cases were more severe and had a higher mean cost. During 2015, IPD costs increased due to an increase in the costs associated with non-PCV13 serotypes and serotype 3 and this requires further investigation. MDPI https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17958
spellingShingle Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
Hernández S
PCV7
PCV13
invasive pneumococcal disease
direct cost
status_str publishedVersion
title Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
title_full Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
title_fullStr Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
title_full_unstemmed Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
title_short Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
title_sort Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
topic PCV7
PCV13
invasive pneumococcal disease
direct cost
topic_facet PCV7
PCV13
invasive pneumococcal disease
direct cost
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17958